TY - JOUR KW - Trachoma KW - Tetracycline KW - Tanzania KW - Secondary Prevention KW - Risk Factors KW - Prospective Studies KW - Prevalence KW - Male KW - Longitudinal studies KW - Infant KW - Humans KW - Female KW - Family Health KW - Endemic Diseases KW - Child, Preschool KW - Child KW - Azithromycin KW - Anti-Bacterial Agents KW - Age Distribution AU - West S AU - Stare D AU - Mkocha HA AU - Munoz B AU - Gaydos C AU - Quinn TC AB -

PURPOSE: Mass treatment with azithromycin for trachoma endemic communities typically excludes infants under age 6 months, whose parents are provided with tubes of tetracycline to administer daily over 4 to 6 weeks. The authors sought to determine whether infants aged <6 months are a source of re-emergent infection in their families after mass treatment in trachoma-endemic communities.

METHODS: In a longitudinal study of all children aged less than 10 years in four communities, the authors identified 91 infants aged <6 months living in 86 of 1241 households. All children aged

RESULTS: The prevalence of infection at baseline in the infants was 5.9%. At 6 months post mass drug administration, the rate of infection among children older than 6 months and less than 10 years who resided in households with infants was 6.0% compared with 11.1% in children in households without infants (P = 0.18). After adjustment for age, sex, baseline infection status, and treatment, residing in a household with an infant was not associated with infection at 6 months (odds ratio [95% confidence interval] 0.50 [0.20-1.22]).

CONCLUSIONS: This prospective study did not find evidence that living in a household with an infant increased the risk of infection 6 months post mass drug administration in other children residing in the household.

BT - Investigative ophthalmology & visual science C1 -

http://www.ncbi.nlm.nih.gov/pubmed/21680866?dopt=Abstract

DO - 10.1167/iovs.11-7372 IS - 8 J2 - Invest. Ophthalmol. Vis. Sci. LA - eng N2 -

PURPOSE: Mass treatment with azithromycin for trachoma endemic communities typically excludes infants under age 6 months, whose parents are provided with tubes of tetracycline to administer daily over 4 to 6 weeks. The authors sought to determine whether infants aged <6 months are a source of re-emergent infection in their families after mass treatment in trachoma-endemic communities.

METHODS: In a longitudinal study of all children aged less than 10 years in four communities, the authors identified 91 infants aged <6 months living in 86 of 1241 households. All children aged

RESULTS: The prevalence of infection at baseline in the infants was 5.9%. At 6 months post mass drug administration, the rate of infection among children older than 6 months and less than 10 years who resided in households with infants was 6.0% compared with 11.1% in children in households without infants (P = 0.18). After adjustment for age, sex, baseline infection status, and treatment, residing in a household with an infant was not associated with infection at 6 months (odds ratio [95% confidence interval] 0.50 [0.20-1.22]).

CONCLUSIONS: This prospective study did not find evidence that living in a household with an infant increased the risk of infection 6 months post mass drug administration in other children residing in the household.

PY - 2011 SP - 6040 EP - 2 T2 - Investigative ophthalmology & visual science TI - Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma? UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176068/pdf/z7g6040.pdf VL - 52 SN - 1552-5783 ER -